enGene | LinkedIn (original) (raw)

Biotechnology Research

Waltham, Massachusetts 15,242 followers

On a mission to mainstream genetic medicines through delivery of therapeutics to mucosal tissues & other organs

About us

enGene (Nasdaq: ENGN) is a clinical-stage biotechnology company mainstreaming genetic medicines. We are unlocking the promise of gene therapy for more patients through localized delivery of non-viral treatments. Founded in Canada, with a United States headquarters in the greater Boston area, our mission is to deliver innovative, locally administered, non-viral genetic medicines to address diseases of high clinical need, including non-muscle invasive bladder cancer (NMIBC), a disease with significant patient burden and massive healthcare system economic impact. To learn more about enGene visit our website: enGene.com. We are currently enrolling select patients with non-muscle invasive bladder cancer (NMIBC) in our LEGEND clinical trial. We have sites in the United States, Canada, Europe and the Asia-Pacific region.

Industry

Biotechnology Research

Company size

11-50 employees

Headquarters

Waltham, Massachusetts

Type

Public Company

Founded

1999

Specialties

gene therapy, urology, oncology, immunotherapy, NMIBC, non-muscle invasive bladder cancer, bladder cancer, DNA, RNA, genetic medicines, Mucosal tissues, non-viral gene therapy, and drug development

Locations

Employees at enGene

Updates

Join now to see what you are missing

Join now

Affiliated pages

Similar pages

Browse jobs

Funding